2 withdrawn, 1 completed, 1 terminated. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow Medeor Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants MDR-103 - Kidney Transplant Rejection | Phase 2 | Withdrawn | Medeor Therapeutics, Inc. | 2024-12-01 | 2024-06-07 | |
| Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants MDR-102, Immunosuppressive Agents - Kidney Transplant Rejection | Phase 2 / Phase 3 | Withdrawn | Medeor Therapeutics, Inc. | 2024-12-01 | 2024-06-07 | |
| Long-term Safety Follow-up in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products MDR product - Immune Tolerance | Terminated | Medeor Therapeutics, Inc. | 5 | 2022-05-11 | 2024-06-07 | |
| Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants MDR-101 - Kidney Transplant Rejection | Phase 3 | Completed | Medeor Therapeutics, Inc. | 30 | 2018-03-15 | 2024-06-07 |
Adrenal Cortex Hormones (1) · Immunosuppressive Agents (1) · Mycophenolic Acid (1) · Tacrolimus (1)
United States (2) · Canada (1)
Lenuta Micsa, MD (3)